## Hussein Khaled

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10734644/publications.pdf

Version: 2024-02-01

471509 477307 32 903 17 29 citations h-index g-index papers 32 32 32 1184 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The changing patterns of bladder cancer in Egypt over the past 26Âyears. Cancer Causes and Control, 2008, 19, 421-429.	1.8	125
2	A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. Journal of Advanced Research, 2015, 6, 375-382.	9.5	93
3	CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Modern Pathology, 2004, 17, 1268-1274.	5.5	71
4	Serum Organochlorine Pesticide Levels in Patients with Colorectal Cancer in Egypt. Archives of Environmental Health, 1997, 52, 409-415.	0.4	64
5	Urinary Bladder Cancer Risk Factors in Egypt: A Multicenter Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 537-546.	2.5	61
6	DNA Copy Number Changes in Schistosoma-Associated and Non-Schistosoma-Associated Bladder Cancer. American Journal of Pathology, 2000, 156, 871-878.	3.8	40
7	Schistosomiasis and Cancer in Egypt: Review. Journal of Advanced Research, 2013, 4, 461-466.	9.5	40
8	Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas, 2010, 67, 353-357.	2.4	37
9	Pesticides, Gene Polymorphisms, and Bladder Cancer Among Egyptian Agricultural Workers. Archives of Environmental and Occupational Health, 2015, 70, 19-26.	1.4	36
10	A review on thyroid cancer during pregnancy: Multitasking is required. Journal of Advanced Research, 2016, 7, 565-570.	9.5	30
11	Familial aggregation of colorectal cancer in Egypt. , 1998, 77, 811-816.		27
12	Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review. Journal of Advanced Research, 2016, 7, 719-726.	9.5	26
13	<i>GSTM1</i> , <i gstt1<="" i=""> Null Variants, and <i gpx1<="" i=""> Single Nucleotide Polymorphism Are Not Associated with Bladder Cancer Risk in Egypt. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1552-1554.</i></i>	2.5	24
14	Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Research and Treatment, 2008, 112, 141-147.	2.5	20
15	A prognostic index (bladder prognostic index) for bilharzial-related invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 254-260.	1.6	19
16	Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients. Breast, 2009, 18, 55-59.	2.2	19
17	Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in E gypt and T unisia. Cancer Medicine, 2013, 2, 178-184.	2.8	19
18	Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary. European Journal of Cancer, 2018, 105, 28-32.	2.8	19

#	Article	IF	Citations
19	Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: A Phase II trial. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 133-136.	1.6	18
20	Agricultural Workers and Urinary Bladder Cancer Risk in Egypt. Archives of Environmental and Occupational Health, 2014, 69, 3-10.	1.4	17
21	Review on renal cell carcinoma and pregnancy: A challenging situation. Journal of Advanced Research, 2016, 7, 575-580.	9.5	15
22	Hepatitis C virus and non-Hodgkin's lymphomas: A minireview. Journal of Advanced Research, 2017, 8, 131-137.	9.5	15
23	Associations differ by sex for catechol-O-methyltransferase genotypes and bladder cancer risk in South Egypt. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 841-847.	1.6	12
24	Genetic polymorphisms in NQO1 and SOD2: Interactions with smoking, schistosoma infection, and bladder cancer risk in Egypt. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e15-47.e20.	1.6	11
25	Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial—an update. Medical Oncology, 2014, 31, 811.	2.5	11
26	The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view. Breast Cancer Research and Treatment, 2018, 172, 545-550.	2.5	7
27	The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study. Molecular Biology Reports, 2020, 47, 9645-9657.	2.3	6
28	Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study. Clinical Breast Cancer, 2020, 20, 228-237.	2.4	6
29	Survival of Inflammatory Breast Cancer Patients Compared to Non-inflammatory Breast Cancer Patients in Egypt. Breast Journal, 2011, 17, 545-547.	1.0	5
30	A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Molecular and Clinical Oncology, 2015, 3, 1099-1102.	1.0	4
31	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. Current Issues in Molecular Biology, 2022, 44, 1332-1352.	2.4	4
32	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. Future Oncology, 2021, 17, 151-157.	2.4	2